Expertise in
15
conditions

Dr. Mark R. Hancock

Internal Medicine
Bozeman Health Big Sky Medical Center LLC
334 Town Ctr Ave, 
Big Sky, MT 
Accepting New Patients
Offers Telehealth
Expertise in
15
conditions
Bozeman Health Big Sky Medical Center LLC
334 Town Ctr Ave, 
Big Sky, MT 

Overview

Mark Hancock is a primary care provider, practicing in Internal Medicine in Big Sky, Montana.

Dr. Hancock is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Neuroendocrine Tumor, Non-Muscle Invasive Bladder Cancer, Muscle Invasive Bladder Cancer, and Lung Cancer.

He is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 10 clinical trials. Dr. Hancock is currently accepting new patients.

Specialties

Internal Medicine

Licenses

Internal Medicine in TX

Hospital Affiliations

Bozeman Health Deaconess Hospital
Regional West Medical Center
Bozeman Health Big Sky Medical Center
Livingston Healthcare
Madison Valley Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Cigna
  • EPO
  • HMO
  • PPO
FirstCare
  • HMO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Mountain Health
  • OTHER COMMERCIAL
  • POS
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

BOZEMAN HEALTH BIG SKY MEDICAL CENTER LLC
334 Town Ctr Ave, Big Sky, MT 59716

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: June 09, 2026
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy
Enrollment Status: Completed
Publish Date: August 21, 2023
Intervention Type: Drug
Study Drugs: Ramucirumab, Docetaxel
Study Phase: Phase 3
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological, Other
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
Enrollment Status: No_longer_available
Publish Date: November 03, 2020
Intervention Type: Drug
View 9 Less Clinical Trials

2 Total Publications

Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non-Small Cell Lung Cancer.
Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non-Small Cell Lung Cancer.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: July 29, 2018
Similar Doctors
Expertise in
6
conditions
Dr. Daniel S. Mitchell
Internal Medicine
Expertise in
6
conditions
Dr. Daniel S. Mitchell
Internal Medicine

Bozeman Health Cardiology Clinic

937 Highland Blvd Ste 5510, 
Bozeman, MT 
 (31.3 miles away)
406-414-3959
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Mitchell is a primary care provider, practicing in Internal Medicine in Bozeman, Montana. Dr. Mitchell is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Miller-Fisher Syndrome, Chronic Polyradiculoneuritis, Guillain-Barre Syndrome, and Chronic B-Cell Leukemia (CBCL). Dr. Mitchell is currently accepting new patients.

Expertise in
6
conditions
Dr. Eric D. Thomas
Internal Medicine
Expertise in
6
conditions
Dr. Eric D. Thomas
Internal Medicine

Hospice Of Montana II LLC

5 W Mendenhall St Ste 202, 
Bozeman, MT 
 (31.7 miles away)
561-678-2026
Experience:
18+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Eric Thomas is a primary care provider, practicing in Internal Medicine in Bozeman, Montana. He has been practicing medicine for over 18 years. Dr. Thomas is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Diabetic Neuropathy, Type 2 Diabetes (T2D), Maturity Onset Diabetes of the Young, and Glucocorticoid-Remediable Aldosteronism.

Expertise in
4
conditions
Dr. Guru N. Khalsa
Internal Medicine
Expertise in
4
conditions
Dr. Guru N. Khalsa
Internal Medicine

Bozeman Health Deaconess Regional Medical Center

915 Highland Blvd, 
Bozeman, MT 
 (31.4 miles away)
406-414-5000
Languages Spoken:
English
See accepted insurances

Guru Khalsa is a primary care provider, practicing in Internal Medicine in Bozeman, Montana. Dr. Khalsa is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Sepsis, Pneumonia, Liver Failure, Endoscopy, and Colonoscopy.

Frequently Asked Questions about Dr. Mark R. Hancock

How do I make an appointment with Dr. Mark R. Hancock?

You can book an appointment with Dr. Mark R. Hancock by calling their office at 406-995-6995. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mark R. Hancock a top-rated expert for Neuroendocrine Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mark R. Hancock is classified as an Advanced expert for Neuroendocrine Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mark R. Hancock specialize in?

While Dr. Mark R. Hancock is a Internal Medicine, they have specific expertise in Neuroendocrine Tumor, Non-Muscle Invasive Bladder Cancer, and Muscle Invasive Bladder Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Mark R. Hancock participate in research or clinical trials?

Yes. Dr. Mark R. Hancock has published 2 articles and abstracts on conditions like Neuroendocrine Tumor. You can view a list of Dr. Mark R. Hancock's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mark R. Hancock accept my insurance?

Dr. Mark R. Hancock accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 406-995-6995 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hancock's expertise for a condition
ConditionClose
      View All 15 Advanced Conditions
      View All 80 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile